Member Posts > Cardiol Therapeutics' CRD-38 and the Future of Non-Oral Heart Failure Treatment
Medication adherence remains a major barrier in heart failure (HF) management. CRD-38, a subcutaneous cannabidiol (CBD) therapy by Cardiol Therapeutics, introduces a novel administration route that could improve compliance and outcomes in HF patients.
Why Non-Oral Therapy Matters
Many HF patients struggle with polypharmacy, leading to poor medication adherence. Subcutaneous delivery of CRD-38 offers:
• Consistent drug levels without reliance on daily pill intake.
• Potential for self-administration, reducing hospital visits.
Mechanistic Insights into CRD-38
• CBD-driven inflammation suppression, targeting cytokines linked to HF progression.
• Organic nitrate-induced vasodilation, improving blood flow to cardiac tissues.
Key Preclinical Findings
• Improved systolic and diastolic function-maintaining efficient heart performance.
• Lowered oxidative stress markers-protecting myocardial cells from damage.
• Reduced myocardial fibrosis-preventing long-term HF deterioration.
Clinical Implications
CRD-38's non-oral route may offer better adherence and efficacy in HF patients who struggle with standard therapies.
Next Steps in Development
Cardiol Therapeutics is advancing towards clinical evaluation, with hopes that CRD-38 will redefine HF treatment strategies.
#CardiolTherapeutics #HeartFailureTreatment #BiotechInvesting #ClinicalTrials #CBDTherapeutics #HeartHealth #MedicalInnovation #PharmaceuticalBreakthroughs